Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Open accessThe DOI matches its Crossref record; 200 of the 200 references it cites were found in a registry or an index.
Abstract
Treatment options for retinal diseases, such as neovascular age-related macular degeneration, diabetic retinopathy, and retinal vascular disorders, have markedly expanded following the development of anti-vascular endothelial growth factor intravitreal injection methods. However, because intravitreal treatment requires monthly or bimonthly repeat injections to achieve optimal efficacy, recent investigations have focused on extended drug delivery systems to lengthen the treatment intervals in the long term. Dose escalation and increasing molecular weight of drugs, intravitreal implants and nanoparticles, hydrogels, combined systems, and port delivery systems are presently under preclinical and clinical investigations. In addition, less invasive techniques rather than intravitreal administration routes, such as topical, subconjunctival, suprachoroidal, subretinal, and trans-scleral, have been evaluated to reduce the treatment burden. Despite the latest advancements in the field of ophthalmic pharmacology, enhancing drug efficacy with high ocular bioavailability while avoiding systemic and local adverse effects is quite challenging. Consequently, despite the performance of numerous in vitro studies, only a few techniques have translated to clinical trials. This review discusses the recent developments in ocular drug delivery to the retina, the pharmacokinetics of intravitreal drugs, efforts to extend drug efficacy in the intraocular space, minimally invasive techniques for drug delivery to the retina, and future perspectives in this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Biodegradable and non-biodegradable ocular implants have been used in several drug treatments for conditions such as diabetic macular edema and posterior uveitis, among others, and provide a method for sustained release of poorly soluble steroids.118,126”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [126]
Experimental — accuracy not yet measuredIn the citing paper
“In the field of ophthalmology, different routes of administration, such as subconjunctival, intravitreal, suprachoroidal and subretinal injections, are commonly used to treat various diseases61.”
From An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species (2024) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Hyaluronic Acid Hydrogels for Biomedical Applications
Burdick, J. A., & Prestwich, G. D. (2011) · Advanced Materials · doi:10.1002/adma.201003963 · Cited by 2,139
Structure and design of polymeric surfactant-based drug delivery systems
Torchilin, V. P. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00299-1 · Cited by 1,822 · cited 2×
“Micelles are nanosized amphiphilic core-shell (hydrophobic core, hydrophilic shell) carriers with polymeric surfactants [91,92].”
BackgroundPolymer nanoparticles: Preparation techniques and size-control parameters
Rao, J. P., & Geckeler, K. E. (2011) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2011.01.001 · Cited by 1,725 · cited 2×
“observed significant suppression of neovascularization [98].”
MethodDendrimer biocompatibility and toxicity
DUNCAN, R., & IZZO, L. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.019 · Cited by 1,158 · cited 1×
“Dendrimers are synthetic three-dimensional repeating-unit branched macromolecules; polyamidoamine (PAMAM) and DAB polypropyleneimine (PPI/DAB) are widely used dendrimers for biomedical purposes [79,80].”
BackgroundRanibizumab for Macular Edema following Central Retinal Vein Occlusion
Brown, D. M., Campochiaro, P. A., Singh, R. P., Li, Z., Gray, S., Saroj, N., Rundle, A. C., Rubio, R. G., & Murahashi, W. Y. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.022 · Cited by 1,155
Hydrogels for Protein Delivery
Vermonden, T., Censi, R., & Hennink, W. E. (2012) · Chemical Reviews · doi:10.1021/cr200157d · Cited by 1,091
Amphiphilic block copolymers for drug delivery
Adams, M. L., Lavasanifar, A., & Kwon, G. S. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10397 · Cited by 1,078
Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects
Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., & Alcudia, A. (2020) · Nanomaterials · doi:10.3390/nano10071403 · Cited by 1,061
Cited by
Items 201–213 of 213
Chitre, A., Dhapte-Pawar, V. S., Sathiyanarayanan, A., & Kanse, A. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127119
Exosomes as emerging biomarkers and therapeutic platforms: From biology to clinical translation
Das, A., Chowdhury, S., Kar, K., Chakraborty, P., & Sarkar, S. (2026) · Biomaterials and Living Medicine for Pharmaceutics · doi:10.1016/j.bioliv.2026.100003
Neuroimmune interactions in retinal ganglion cell degeneration
Li, B., Shi, Y., Song, K., Zhang, M., Yan, Y., Ning, B., & 亢泽峰 (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-03101-w
“…Signal transducer and activator of transcription 3, JAK2 Janus kinase 2, COH Chronic intraocular hypertension delivery of therapeutic agents to sites of retinal injury, while increasing local drug concentrations and minimizing systemic adverse effects, remains a key technical challenge [242, 243].”
Das, S., Behera, A., Pattnaik, G., Acharya, B., HABIBULLAH, S., & Mohanty, B. (2026) · Next Nanotechnology · doi:10.1016/j.nxnano.2026.100644
Desiato, A., Iyire, A., & Gil-Cazorla, R. (2026) · Pharmaceuticals · doi:10.3390/ph19081222
“Although regulatory approval has been achieved for other ophthalmic drug-delivery devices, including a drug-eluting contact lens, an equivalent, comprehensive evaluation framework has not been established for ocular inserts, whether film-based or otherwise [29,137].”
Cellular senescence in diabetic retinopathy: Molecular mechanisms and therapeutic targeting
Liu, W., Gao, J., Zhang, X., Yang, F., Jiao, M., Chang, J., Su, L., & Li, X. (2026) · Advances in Ophthalmology Practice and Research · doi:10.1016/j.aopr.2026.07.002
Boglárka, S. (2026) · SZTE Repository of Dissertations (University of Szeged)
Biomaterials in Retinal Surgery: Engineering the Future
Dindar, I. A., Shoichet, M. S., Labriola, J. M., Forman, A., & Devenyi, R. G. (2026) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2026.08.039
Tomazoni, E., Penha, F. M., & Rodrigues, E. B. (2026) · Springer eBooks · doi:10.1007/978-3-032-23052-2_18
Basics of Intraocular Pharmacotherapy
Melo, G. B., & Badaró, E. (2026) · Springer eBooks · doi:10.1007/978-3-032-23052-2_17
Stem cell secretome- and extracellular vesicle-based therapies for retinal pathologies
Capobianco, M., Cappellani, F., Enaholo, E. S., & Zeppieri, M. (2026) · World Journal of Stem Cells · doi:10.4252/wjsc.125852
Weener, M. E., & Kotliar, K. E. (2026) · Cells · doi:10.3390/cells15211931
Designing Enzyme-Sensitive Polymers as Site-Specific Delivery Systems for Ocular Therapies
Harzand, F. V., Mousavi, S. M., Yang, C.-J., & Lai, J. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.6c00165
Metadata
- Authors
- Kim, H. M., & Woo, S. J.
- Affiliations
- Seoul National University (KR)
- Corresponding author
- Woo, Se Joon
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2021-01-15
- Volume
- 13
- Issue
- 1
- Pages
- 108
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC7830424
- OpenAlex
- W3118619250
- Cited by
- 198
- References
- 200
- Citations by year
- 2026: 27 · 2025: 40 · 2024: 35 · 2023: 44 · 2022: 33 · 2021: 18
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation (2020R1F1A1072795, 2018M3A9B5021319)
- National Research Foundation of Korea (2020R1F1A1072795, 2018M3A9B5021319)
- Ministry of Science and ICT, South Korea (2020R1F1A1072795)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- ocular drug delivery, retinal drug delivery, intravitreal injection, intravitreal implant, nanoparticles, hydrogels, port delivery system, anti-VEGF therapy, neovascular age-related macular degeneration, diabetic retinopathy, retinal vascular disease, subconjunctival administration, ocular bioavailability, minimally invasive drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.